Essential tremor

disease

On this page

Also known as essential hereditary tremortremor, hereditary essential

Summary

Essential tremor (MONDO:0003233) is a disease (an umbrella term covering 6 Mondo subtypes) with 31 cohort genes (119 GWAS associations across 11 studies) and 235 clinical trials. Top therapeutic interventions include propranolol, oxybate, and zonisamide.

At a glance

Umbrella term: 6 Mondo subtypes
Cohort genes: 31
GWAS associations: 119
ClinVar variants: 27
Clinical trials: 235

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	essential tremor
Mondo ID	MONDO:0003233
EFO	EFO:0003108
MeSH	D020329
OMIM	190300
Orphanet	862
DOID	DOID:4990
ICD-10-CM	G25.0
SNOMED CT	609558009
UMLS	C0270736
MedGen	78725
Is cancer (heuristic)	no

Also known as: essential hereditary tremor · tremor, hereditary essential

Data availability: 27 ClinVar variants · 119 GWAS associations (11 studies) · 1 GenCC gene-disease record.

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › movement disorder › essential tremor

Subtypes (6): tremor, hereditary essential, 1, tremor, hereditary essential, 2, tremor, hereditary essential, 3, tremor, hereditary essential, 4, tremor, hereditary essential, 5, tremor, hereditary essential, 6

Genetics & variants

GWAS landscape

119 GWAS associations across 11 studies. Top hits map to 25 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs9980363	5e-24	LINC00323	C	1.15
rs1945016	3e-18	MIR924HG	T	0.9
chr21:42521711	5e-16		A	0.11
rs17649684	4e-15	PPARGC1A - DHX15	C	0.89
rs17432566	5e-15	EHBP1	G	1.13
rs13128363	9e-15	CPLX1	T	1.14
chr2:63142090	1e-14		G	0.13
rs17650401	2e-14	PPARGC1A - DHX15	T	1.18
rs4733870	7e-14	LINC00824	A	1.12
rs9982271	8e-14	LINC00323	C	0.11
rs11749692	4e-13	PIK3R1 - LINC02198	G	1.09
chr5:67826734	8e-13		G	0.09
rs79009191	1e-12	EHBP1	A	0.13
rs955007	1e-12	CA3-AS1	C	0.92
rs2078396	5e-12	PIK3R1 - LINC02198	C	0.09
chr6:43255380	1e-11		G	0.13
rs139378881	3e-11	SLC24A2	G	0.43
rs9843219	6e-11	IL20RB - RNA5SP142	G	0.93
rs7042473	1e-10	CDC14B	T	0.91
rs10937625	5e-10	STK32B	T	1.25
rs9652490	1e-09	LINGO1	G	1.55
rs17590046	1e-09	PPARGC1A - DHX15	T	1.27
rs12764057	1e-08	CTNNA3, LRRTM3	G	1.17
rs1260326	1e-08	GCKR	T	0.94
rs10109552	2e-08	NAT2 - PSD3	G	1.23
rs1482967	3e-08	MIR924HG	G	1.1
rs1127215	3e-08	PTGFRN	C	1.09
rs28562175	3e-08	PIK3R1 - LINC02198	C	0.92
rs182213143	3e-08	CAMKMT - LINC01833	?
rs3794087	1e-07	SLC1A2	?	1.43

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90832977	Skuladottir AT	2024	16,480	1,936,173	GWAS meta-analysis reveals key risk loci in essential tremor pathogenesis.
GCST90475832	Verma A	2024	13,720	429,794	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90101814	Liao C	2022	7,177	475,877	Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.
GCST003762	Muller SH	2016	1,778	5,376	Genome-wide association study in essential tremor identifies three new loci.
GCST90477513	Verma A	2024	1,505	119,311	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480009	Verma A	2024	1,505	119,311	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477512	Verma A	2024	920	58,304	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651621	Liu TY	2025	863	218,635	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST000329	Stefansson H	2009	452	14,378	Variant in the sequence of the LINGO1 gene confers risk of essential tremor.
GCST001590	Thier S	2012	436	0	Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	2
Tier 3: regulatory	0
Tier 4: intronic/intergenic	47

MAF distribution

Bucket	Variants
common (>=0.05)	48
low_freq (0.01-0.05)	0
rare (<0.01)	1
unknown	1

Functional consequences

Consequence	Count
intron_variant	31
intergenic_variant	10
unknown	4
non_coding_transcript_exon_variant	2
missense_variant	1
3_prime_UTR_variant	1
5_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs9980363	21	41148207	T>C	0.05	intron_variant	LINC00323	5e-24	Tier 4: intronic/intergenic
rs1945016	18	39627211	T>G	0.05	intron_variant	MIR924HG	3e-18	Tier 4: intronic/intergenic
chr21:42521711				0.212			5e-16	Tier 4: intronic/intergenic
rs17649684	4	24357496	T>C	0.05	intergenic_variant	PPARGC1A - DHX15	4e-15	Tier 4: intronic/intergenic
rs17432566	2	62918274	A>C,G	0.05	intron_variant	EHBP1	5e-15	Tier 4: intronic/intergenic
rs13128363	4	786761	C>G,T	0.05	intron_variant	CPLX1	9e-15	Tier 4: intronic/intergenic
chr2:63142090				0.132			1e-14	Tier 4: intronic/intergenic
rs17650401	4	24374210	C>A,T	0.05	intergenic_variant	PPARGC1A - DHX15	2e-14	Tier 4: intronic/intergenic
rs4733870	8	128444882	A>C,G,T	0.05	intron_variant	LINC00824	7e-14	Tier 4: intronic/intergenic
rs9982271	21	41147462	C>T	0.188	non_coding_transcript_exon_variant	LINC00323	8e-14	Tier 4: intronic/intergenic
rs11749692	5	68535994	A>G	0.05	intron_variant	PIK3R1 - LINC02198	4e-13	Tier 4: intronic/intergenic
chr5:67826734				0.372			8e-13	Tier 4: intronic/intergenic
rs79009191	2	62898196	A>G,T	0.108	intron_variant	EHBP1	1e-12	Tier 4: intronic/intergenic
rs955007	8	85458166	C>A	0.05	intron_variant	CA3-AS1	1e-12	Tier 4: intronic/intergenic
rs2078396	5	68538416	C>T	0.377	intron_variant	PIK3R1 - LINC02198	5e-12	Tier 4: intronic/intergenic
chr6:43255380				0.105			1e-11	Tier 4: intronic/intergenic
rs139378881	9	19760782	G>A	0.008	intron_variant	SLC24A2	3e-11	Tier 4: intronic/intergenic
rs9843219	3	137087450	T>G	0.05	intergenic_variant	IL20RB - RNA5SP142	6e-11	Tier 4: intronic/intergenic
rs7042473	9	96584288	C>G,T	0.05	intron_variant	CDC14B	1e-10	Tier 4: intronic/intergenic
rs10937625	4	5126432	T>C	0.264	intron_variant	STK32B	5e-10	Tier 4: intronic/intergenic
rs9652490	15	77671545	A>G,T	0.23	intron_variant	LINGO1	1e-09	Tier 4: intronic/intergenic
rs17590046	4	24360918	T>C	0.207	intergenic_variant	PPARGC1A - DHX15	1e-09	Tier 4: intronic/intergenic
rs12764057	10	67085957	T>G	0.367	intron_variant	CTNNA3, LRRTM3	1e-08	Tier 4: intronic/intergenic
rs1260326	2	27508073	T>A,C,G	0.05	missense_variant	GCKR	1e-08	Tier 1: coding
rs10109552	8	18451300	T>C,G	0.259	intergenic_variant	NAT2 - PSD3	2e-08	Tier 4: intronic/intergenic
rs1482967	18	39494462	A>G	0.436	intron_variant	MIR924HG	3e-08	Tier 4: intronic/intergenic
rs1127215	1	116990168	C>A,T	0.409	3_prime_UTR_variant	PTGFRN	3e-08	Tier 2: splice/UTR
rs28562175	5	68531629	C>A,T	0.377	intron_variant	PIK3R1 - LINC02198	3e-08	Tier 4: intronic/intergenic
rs182213143	2	44794805	C>G		intron_variant	CAMKMT - LINC01833	3e-08	Tier 4: intronic/intergenic
rs3794087	11	35308068	G>A,C,T	0.05	intron_variant	SLC1A2	1e-07	Tier 4: intronic/intergenic

ClinVar germline variants

27 retrieved; paginated sample, class counts are floors:

18 uncertain significance, 4 likely pathogenic, 2 benign, 2 likely benign, 1 conflicting classifications of pathogenicity

ClinVar	Variant (HGVS)	Gene	Classification	Review
4526876	NM_014289.4(CAPN6):c.860G>A (p.Gly287Glu)	CAPN6	Likely pathogenic	no assertion criteria provided
1184863	NM_001039374.5(CCDC183):c.1025G>A (p.Trp342Ter)	CCDC183	Likely pathogenic	no assertion criteria provided
523937	NM_004999.4(MYO6):c.2751dup (p.Gln918fs)	MYO6	Likely pathogenic	reviewed by expert panel
1184858	NM_003241.4(TGM4):c.806G>A (p.Trp269Ter)	TGM4	Likely pathogenic	no assertion criteria provided
56171	NM_015268.4(DNAJC13):c.2564A>G (p.Asn855Ser)	DNAJC13	Conflicting classifications of pathogenicity	no assertion criteria provided
4526878	NM_152701.5(ABCA13):c.13663T>C (p.Tyr4555His)	ABCA13	Uncertain significance	no assertion criteria provided
4526879	NM_015268.4(DNAJC13):c.805A>G (p.Thr269Ala)	DNAJC13	Uncertain significance	no assertion criteria provided
4526880	NM_015268.4(DNAJC13):c.1713+60T>A	DNAJC13	Uncertain significance	no assertion criteria provided
1184857	NM_001145710.2(FAM228B):c.907del (p.Gln303fs)	FAM228B	Uncertain significance	no assertion criteria provided
4526872	NM_000146.4(FTL):c.183G>C (p.Glu61Asp)	FTL	Uncertain significance	no assertion criteria provided
4526881	NM_002043.5(GABRR2):c.655A>T (p.Thr219Ser)	GABRR2	Uncertain significance	no assertion criteria provided
1184862	NM_015465.5(GEMIN5):c.2519_2522del (p.Ile840fs)	GEMIN5	Uncertain significance	no assertion criteria provided
4526877	NM_144633.3(KCNH8):c.2663T>C (p.Met888Thr)	KCNH8	Uncertain significance	no assertion criteria provided
1184864	NM_002425.3(MMP10):c.32_33del (p.Cys11fs)	MMP10	Uncertain significance	no assertion criteria provided
1184865	NM_032597.5(MS4A14):c.167_168dup (p.Val57fs)	MS4A14	Uncertain significance	no assertion criteria provided
1184860	NM_001005516.1(OR5K3):c.904del (p.Ile302fs)	OR5K3	Uncertain significance	no assertion criteria provided
1184859	NM_001005517.1(OR5K4):c.901dup (p.Ile301fs)	OR5K4	Uncertain significance	no assertion criteria provided
1184811	NM_001005182.2(OR6C1):c.24del (p.Glu9fs)	OR6C1	Uncertain significance	no assertion criteria provided
4526871	NM_015715.5(PLA2G3):c.782+1G>C	PLA2G3	Uncertain significance	no assertion criteria provided
1184861	NM_183375.5(PRSS48):c.127_131del (p.Val43fs)	SH3D19	Uncertain significance	no assertion criteria provided
4526874	NM_001098816.3(TENM4):c.5158A>G (p.Thr1720Ala)	TENM4	Uncertain significance	no assertion criteria provided
4526873	NM_001330987.2(TMEM230):c.251A>C (p.Lys84Thr)	TMEM230	Uncertain significance	no assertion criteria provided
4526875	NM_001130698.2(TRPC3):c.1661T>C (p.Ile554Thr)	TRPC3	Uncertain significance	no assertion criteria provided
774620	NM_144666.3(DNHD1):c.2839G>T (p.Glu947Ter)	DNHD1	Likely benign	criteria provided, multiple submitters, no conflicts
782100	NM_194251.3(GPR151):c.283C>T (p.Arg95Ter)	GPR151	Benign	criteria provided, single submitter
769495	NM_181536.2(PKD1L3):c.3695_3698del (p.Thr1232fs)	PKD1L3	Benign	criteria provided, single submitter
778175	NM_032423.3(ZNF528):c.1282C>T (p.Arg428Ter)	ZNF528	Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 7 · Orphanet: 18 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
TUB	Limited	Autosomal dominant	essential tremor	7

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TUB	Orphanet:791	Retinitis pigmentosa
SLC1A2	Orphanet:442835	Non-specific early-onset epileptic encephalopathy
TRPC3	Orphanet:458798	Spinocerebellar ataxia type 41
GEMIN5	Orphanet:88616	Autosomal recessive non-syndromic intellectual disability
CTNNA3	Orphanet:293888	Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
CTNNA3	Orphanet:293899	Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant
CTNNA3	Orphanet:293910	Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
DNHD1	Orphanet:137893	Male infertility due to large-headed multiflagellar polyploid spermatozoa
DNHD1	Orphanet:399805	Male infertility with azoospermia or oligozoospermia due to single gene mutation
DNAJC13	Orphanet:411602	Hereditary late-onset Parkinson disease
FTL	Orphanet:157846	Neuroferritinopathy
FTL	Orphanet:163	Hereditary hyperferritinemia-cataract syndrome
FTL	Orphanet:254704	Genetic hyperferritinemia without iron overload
FTL	Orphanet:440731	L-ferritin deficiency
MYO6	Orphanet:228012	Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome
MYO6	Orphanet:90635	Rare autosomal dominant non-syndromic sensorineural deafness type DFNA
MYO6	Orphanet:90636	Rare autosomal recessive non-syndromic sensorineural deafness type DFNB
PPARGC1A	Orphanet:803	Amyotrophic lateral sclerosis

Cohort genes → proteins

31 cohort genes, 31 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	5
multi_evidence	26

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TUB	HGNC:12406	ENSG00000166402	P50607	Tubby protein homolog	gencc
SLC1A2	HGNC:10940	ENSG00000110436	P43004	Excitatory amino acid transporter 2	gwas
TGM4	HGNC:11780	ENSG00000163810	P49221	Protein-glutamine gamma-glutamyltransferase 4	clinvar
TRPC3	HGNC:12335	ENSG00000138741	Q13507	Short transient receptor potential channel 3	clinvar
STK32B	HGNC:14217	ENSG00000152953	Q9NY57	Serine/threonine-protein kinase 32B	gwas
ABCA13	HGNC:14638	ENSG00000179869	Q86UQ4	ATP-binding cassette sub-family A member 13	clinvar
CAPN6	HGNC:1483	ENSG00000077274	Q9Y6Q1	Calpain-6	clinvar
TMEM230	HGNC:15876	ENSG00000089063	Q96A57	Transmembrane protein 230	clinvar
PLA2G3	HGNC:17934	ENSG00000100078	Q9NZ20	Group 3 secretory phospholipase A2	clinvar
KCNH8	HGNC:18864	ENSG00000183960	Q96L42	Voltage-gated delayed rectifier potassium channel KCNH8	clinvar
GEMIN5	HGNC:20043	ENSG00000082516	Q8TEQ6	Gem-associated protein 5	clinvar
LINGO1	HGNC:21205	ENSG00000169783	Q96FE5	Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1	gwas
PKD1L3	HGNC:21716	ENSG00000277481	Q7Z443	Polycystin-1-like protein 3	clinvar
GPR151	HGNC:23624	ENSG00000173250	Q8TDV0	G-protein coupled receptor 151	clinvar
FAM228B	HGNC:24736	ENSG00000219626	P0C875	Protein FAM228B	clinvar
CTNNA3	HGNC:2511	ENSG00000183230	Q9UI47	Catenin alpha-3	gwas
DNHD1	HGNC:26532	ENSG00000179532	Q96M86	Dynein heavy chain domain-containing protein 1	clinvar
CCDC183	HGNC:28236	ENSG00000213213	Q5T5S1	Coiled-coil domain-containing protein 183	clinvar
ZNF528	HGNC:29384	ENSG00000167555	Q3MIS6	Zinc finger protein 528	clinvar
TENM4	HGNC:29945	ENSG00000149256	Q6N022	Teneurin-4	clinvar
DNAJC13	HGNC:30343	ENSG00000138246	O75165	DnaJ homolog subfamily C member 13	clinvar
SH3D19	HGNC:30418	ENSG00000109686	Q5HYK7	SH3 domain-containing protein 19	clinvar
MS4A14	HGNC:30706	ENSG00000166928	Q96JA4	Membrane-spanning 4-domains subfamily A member 14	clinvar
OR5K3	HGNC:31290	ENSG00000206536	A6NET4	Olfactory receptor 5K3	clinvar
OR5K4	HGNC:31291	ENSG00000196098	A6NMS3	Olfactory receptor 5K4	clinvar
FTL	HGNC:3999	ENSG00000087086	P02792	Ferritin light chain	clinvar
GABRR2	HGNC:4091	ENSG00000111886	P28476	Gamma-aminobutyric acid receptor subunit rho-2	clinvar
MMP10	HGNC:7156	ENSG00000166670	P09238	Stromelysin-2	clinvar
MYO6	HGNC:7605	ENSG00000196586	Q9UM54	Unconventional myosin-VI	clinvar
OR6C1	HGNC:8355	ENSG00000205330	Q96RD1	Olfactory receptor 6C1	clinvar
PPARGC1A	HGNC:9237	ENSG00000109819	Q9UBK2	Peroxisome proliferator-activated receptor gamma coactivator 1-alpha	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TUB	Tubby protein homolog	Functions in signal transduction from heterotrimeric G protein-coupled receptors.
SLC1A2	Excitatory amino acid transporter 2	Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate.
TGM4	Protein-glutamine gamma-glutamyltransferase 4	Associated with the mammalian reproductive process.
TRPC3	Short transient receptor potential channel 3	Forms a receptor-activated non-selective calcium permeant cation channel.
ABCA13	ATP-binding cassette sub-family A member 13	May mediate the cholesterol and gangliosides transport from the plasma membrane to intracellular vesicles in an ATP hydrolysis dependent manner, thus playing a role in their internalization by endocytic retrograde transport and may also pa…
CAPN6	Calpain-6	Microtubule-stabilizing protein that may be involved in the regulation of microtubule dynamics and cytoskeletal organization.
TMEM230	Transmembrane protein 230	Involved in trafficking and recycling of synaptic vesicles.
PLA2G3	Group 3 secretory phospholipase A2	Secretory calcium-dependent phospholipase A2 that primarily targets extracellular phospholipids.
KCNH8	Voltage-gated delayed rectifier potassium channel KCNH8	Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents.
GEMIN5	Gem-associated protein 5	The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs.
LINGO1	Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1	Functional component of the Nogo receptor signaling complex (RTN4R/NGFR) in RhoA activation responsible for some inhibition of axonal regeneration by myelin-associated factors.
PKD1L3	Polycystin-1-like protein 3	Pore-forming subunit of a heterotetrameric, non-selective cation channel that is permeable to Ca(2+).
GPR151	G-protein coupled receptor 151	Proton-sensing G-protein coupled receptor.
CTNNA3	Catenin alpha-3	May be involved in formation of stretch-resistant cell-cell adhesion complexes.
DNHD1	Dynein heavy chain domain-containing protein 1	Essential for the normal assembly and function of sperm flagella axonemes.
ZNF528	Zinc finger protein 528	May be involved in transcriptional regulation.
TENM4	Teneurin-4	Involved in neural development, regulating the establishment of proper connectivity within the nervous system.
DNAJC13	DnaJ homolog subfamily C member 13	Involved in membrane trafficking through early endosomes, such as the early endosome to recycling endosome transport implicated in the recycling of transferrin and the early endosome to late endosome transport implicated in degradation of…
SH3D19	SH3 domain-containing protein 19	May play a role in regulating A disintegrin and metalloproteases (ADAMs) in the signaling of EGFR-ligand shedding.
MS4A14	Membrane-spanning 4-domains subfamily A member 14	May be involved in signal transduction as a component of a multimeric receptor complex.
OR5K3	Olfactory receptor 5K3	Odorant receptor.
OR5K4	Olfactory receptor 5K4	Odorant receptor.
FTL	Ferritin light chain	Stores iron in a soluble, non-toxic, readily available form.
GABRR2	Gamma-aminobutyric acid receptor subunit rho-2	Rho subunit of the pentameric ligand-gated chloride channels responsible for mediating the effects of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain.
MMP10	Stromelysin-2	Can degrade fibronectin, gelatins of type I, III, IV, and V; weakly collagens III, IV, and V.
MYO6	Unconventional myosin-VI	Myosins are actin-based motor molecules with ATPase activity.
OR6C1	Olfactory receptor 6C1	Odorant receptor.
PPARGC1A	Peroxisome proliferator-activated receptor gamma coactivator 1-alpha	Transcriptional coactivator for steroid receptors and nuclear receptors.

Protein-family classification

Druggable: 12 · Difficult: 4 · Unknown: 15 · Druggable fraction: 0.39

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Ion channel	2	7.2×	0.175
GPCR	4	3.1×	0.175
Transporter	1	2.5×	0.496
Protease	2	2.4×	0.496
Antibody/Immunoglobulin	2	1.9×	0.496
Scaffold/PPI	3	1.7×	0.496
Kinase	1	0.9×	0.874
Other/Unknown	15	0.9×	0.950
Transcription factor	1	0.3×	0.982

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TUB	Other/Unknown	no		Tubby_C, Tubby_N, Tubby_C_CS
SLC1A2	Other/Unknown	no		Na-dicarboxylate_symporter, Na-dicarboxylate_symporter_CS, Na:dicarbo_symporter_sf
TGM4	Antibody/Immunoglobulin	yes	2.3.2.13	Transglutaminase_N, Transglutaminase-like, Transglutaminase_C
TRPC3	Ion channel	yes		Ankyrin_rpt, TRPC_channel, TRPC3_channel
STK32B	Kinase	yes		Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf
ABCA13	Transporter	yes		ABC_transporter-like_ATP-bd, AAA+_ATPase, ABC2_TM
CAPN6	Protease	yes	3.4.22.B26	C2_dom, Peptidase_C2_calpain_cat, Calpain_domain_III
TMEM230	Other/Unknown	no		TMEM_230/134, TMEM230
PLA2G3	Other/Unknown	no		PLA2-like_dom, PLA2_histidine, PLipase_A2_dom_sf
KCNH8	Ion channel	yes		PAS, cNMP-bd_dom, PAS-assoc_C
GEMIN5	Scaffold/PPI	no		WD40_rpt, Quinoprotein_ADH-like_sf, WD40/YVTN_repeat-like_dom_sf
LINGO1	Antibody/Immunoglobulin	yes		LRRNT, Leu-rich_rpt, Leu-rich_rpt_typical-subtyp
PKD1L3	Other/Unknown	no		GPS, PC1, PLAT/LH2_dom
GPR151	GPCR	yes		GPCR_Rhodpsn, GPCR_Rhodpsn_7TM
FAM228B	Other/Unknown	no		FAM228
CTNNA3	Other/Unknown	no		Alpha_catenin, Vinculin/catenin, Alpha-catenin/vinculin-like_sf
DNHD1	Other/Unknown	no		Dhc_D6_P-loop, Dhc_linker, Dhc_D4
CCDC183	Other/Unknown	no		CCDC183
ZNF528	Transcription factor	no		KRAB, Znf_C2H2_type, KRAB_dom_sf
TENM4	Other/Unknown	no		EGF, YD, CarboxyPept-like_regulatory
DNAJC13	Other/Unknown	no		DnaJ_domain, ARM-like, ARM-type_fold
SH3D19	Scaffold/PPI	no		SH3_domain, Eve1_SH3_1, Eve1_SH3_3
MS4A14	Other/Unknown	no		CD20-like_TM, MS4A
OR5K3	GPCR	yes		GPCR_Rhodpsn, Olfact_rcpt, GPCR_Rhodpsn_7TM
OR5K4	GPCR	yes		GPCR_Rhodpsn, Olfact_rcpt, GPCR_Rhodpsn_7TM
FTL	Other/Unknown	no		Ferritin, Ferritin_DPS_dom, Ferritin-like_diiron
GABRR2	Other/Unknown	no		GABAA/Glycine_rcpt, Neurotrans-gated_channel_TM, Neur_channel
MMP10	Protease	yes	3.4.24.22	Hemopexin-like_dom, Pept_M10_metallopeptidase, Peptidoglycan-bd-like
MYO6	Scaffold/PPI	no		Myosin_head_motor_dom-like, SH3_Myosin, Myosin_S1_N
OR6C1	GPCR	yes		GPCR_Rhodpsn, Olfact_rcpt, GPCR_Rhodpsn_7TM
PPARGC1A	Other/Unknown	no		RRM_dom, Nucleotide-bd_a/b_plait_sf, PGC-1

Expression context

Cohort genes with no expression data: 0.

24 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	3
moderate (6-20)	1
broad (>20)	27
unknown	0

Top tissues across cohort

Tissue	Cohort genes
buccal mucosa cell	4
C1 segment of cervical spinal cord	4
left testis	4
male germ line stem cell (sensu Vertebrata) in testis	3
oocyte	3
secondary oocyte	3
corpus callosum	3
calcaneal tendon	3
right testis	3
colonic epithelium	3
endothelial cell	2
gall bladder	2
prefrontal cortex	2
medial globus pallidus	2
sural nerve	2
ventricular zone	2
granulocyte	2
middle temporal gyrus	1
substantia nigra pars compacta	1
substantia nigra pars reticulata	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TUB	240	ubiquitous	marker	substantia nigra pars reticulata, substantia nigra pars compacta, middle temporal gyrus
SLC1A2	227	broad	marker	endothelial cell, entorhinal cortex, Brodmann (1909) area 23
TGM4	100	tissue_specific	yes	male germ line stem cell (sensu Vertebrata) in testis, prostate gland, bone marrow
TRPC3	163	broad	marker	buccal mucosa cell, secondary oocyte, oocyte
STK32B	177	broad	marker	secondary oocyte, buccal mucosa cell, oocyte
ABCA13	126	broad	marker	bronchial epithelial cell, bronchus, epithelium of nasopharynx
CAPN6	161	broad	marker	cauda epididymis, caput epididymis, tibia
TMEM230	145	ubiquitous	marker	gall bladder, C1 segment of cervical spinal cord, right adrenal gland cortex
PLA2G3	109	broad	marker	cervix squamous epithelium, gingival epithelium, gingiva
KCNH8	168	broad	marker	corpus callosum, endothelial cell, C1 segment of cervical spinal cord
GEMIN5	236	ubiquitous	marker	oocyte, secondary oocyte, tibialis anterior
LINGO1	200	broad	yes	cortical plate, prefrontal cortex, right frontal lobe
PKD1L3	42	tissue_specific	marker	male germ line stem cell (sensu Vertebrata) in testis, right lobe of liver, liver
GPR151	16		marker	prefrontal cortex, C1 segment of cervical spinal cord, Brodmann (1909) area 9
FAM228B	245	ubiquitous	marker	calcaneal tendon, C1 segment of cervical spinal cord, left testis
CTNNA3	211	broad	marker	corpus callosum, heart right ventricle, medial globus pallidus
DNHD1	178	tissue_specific	marker	right testis, left testis, sural nerve
CCDC183	133	broad	yes	left testis, right testis, testis
ZNF528	197	ubiquitous	marker	buccal mucosa cell, sural nerve, calcaneal tendon
TENM4	228	ubiquitous	marker	hair follicle, ganglionic eminence, lateral nuclear group of thalamus
DNAJC13	297	ubiquitous	marker	calcaneal tendon, buccal mucosa cell, saphenous vein
SH3D19	256	ubiquitous	marker	tendon of biceps brachii, left ventricle myocardium, ileal mucosa
MS4A14	172	tissue_specific	marker	sperm, left testis, right testis
OR5K3	4		yes	male germ line stem cell (sensu Vertebrata) in testis, colonic epithelium, ventricular zone
OR5K4	4		yes	primordial germ cell in gonad, granulocyte, colonic epithelium
FTL	134	ubiquitous	marker	stromal cell of endometrium, blood, gall bladder
GABRR2	161	tissue_specific	yes	type B pancreatic cell, olfactory bulb, diaphragm
MMP10	124	broad	marker	mucosa of paranasal sinus, olfactory segment of nasal mucosa, palpebral conjunctiva
MYO6	278	ubiquitous	marker	amniotic fluid, medial globus pallidus, corpus callosum
OR6C1	0		yes	granulocyte, colonic epithelium, ventricular zone

Protein interactions among cohort

Intra-cohort edges: 6.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PPARGC1A	5,889
SLC1A2	3,184
MYO6	2,972
GEMIN5	2,805
FTL	2,767
LINGO1	2,401
CTNNA3	2,306
MMP10	1,756
DNAJC13	1,724
PLA2G3	1,612

Intra-cohort edges

A	B	Sources
CCDC183	GPR151	string_interaction
CCDC183	STK32B	string_interaction
CCDC183	TENM4	string_interaction
CTNNA3	STK32B	string_interaction
DNAJC13	TMEM230	string_interaction
LINGO1	STK32B	string_interaction

Structural data

PDB: 11 · AlphaFold-only: 20 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
PPARGC1A	Q9UBK2	47
TRPC3	Q13507	19
FTL	P02792	17
GEMIN5	Q8TEQ6	16
MYO6	Q9UM54	8
SLC1A2	P43004	7
TENM4	Q6N022	4
MMP10	P09238	4
LINGO1	Q96FE5	2
GPR151	Q8TDV0	2
TUB	P50607	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
TGM4	P49221	92.09
CAPN6	Q9Y6Q1	91.57
OR6C1	Q96RD1	90.34
OR5K4	A6NMS3	86.95
STK32B	Q9NY57	86.38
OR5K3	A6NET4	82.94
DNAJC13	O75165	82.91
CCDC183	Q5T5S1	81.98
CTNNA3	Q9UI47	81.65
TMEM230	Q96A57	81.46
GABRR2	P28476	77.00
PLA2G3	Q9NZ20	71.88
ZNF528	Q3MIS6	71.22
FAM228B	P0C875	68.53
PKD1L3	Q7Z443	65.18
KCNH8	Q96L42	64.41
SH3D19	Q5HYK7	59.09
MS4A14	Q96JA4	48.59
ABCA13	Q86UQ4
DNHD1	Q96M86

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 65. Enrichment computed across 31 evidence-associated genes (19 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 19 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Regulation of MITF-M dependent genes involved in metabolism	1	200.3×	0.099	PPARGC1A
p75NTR regulates axonogenesis	1	120.2×	0.099	LINGO1
SLC-mediated transport of amino acids	1	120.2×	0.099	SLC1A2
Astrocytic Glutamate-Glutamine Uptake And Metabolism	1	100.2×	0.099	SLC1A2
Axonal growth inhibition (RHOA activation)	1	66.8×	0.099	LINGO1
Activation of PPARGC1A (PGC-1alpha) by phosphorylation	1	60.1×	0.099	PPARGC1A
Role of second messengers in netrin-1 signaling	1	54.6×	0.099	TRPC3
Gap junction degradation	1	50.1×	0.099	MYO6
RHOBTB GTPase Cycle	1	42.9×	0.099	MYO6
Glutamate binding, activation of AMPA receptors and synaptic plasticity	1	40.1×	0.099	MYO6
Elevation of cytosolic Ca2+ levels	1	37.6×	0.099	TRPC3
Acyl chain remodelling of PG	1	33.4×	0.099	PLA2G3
Scavenging by Class A Receptors	1	31.6×	0.099	FTL
MECP2 regulates neuronal receptors and channels	1	31.6×	0.099	TRPC3
Trafficking of AMPA receptors	1	28.6×	0.099	MYO6
Gap junction trafficking and regulation	1	25.0×	0.099	MYO6
Gap junction trafficking	1	25.0×	0.099	MYO6
RHOBTB2 GTPase cycle	1	25.0×	0.099	MYO6
RHOBTB1 GTPase cycle	1	25.0×	0.099	MYO6
Effects of PIP2 hydrolysis	1	24.0×	0.099	TRPC3
Glutamate Neurotransmitter Release Cycle	1	24.0×	0.099	SLC1A2
Acyl chain remodelling of PC	1	22.3×	0.099	PLA2G3
TRP channels	1	21.5×	0.099	TRPC3
RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	1	21.5×	0.099	PPARGC1A
Golgi Associated Vesicle Biogenesis	2	21.1×	0.099	SH3D19, FTL
Acyl chain remodelling of PE	1	20.7×	0.099	PLA2G3
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	1	20.0×	0.099	PPARGC1A
Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	1	20.0×	0.099	PPARGC1A
Degradation of the extracellular matrix	2	12.4×	0.099	CAPN6, MMP10
Extracellular matrix organization	2	6.6×	0.099	CAPN6, MMP10

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 25 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
neurotransmitter reuptake	1	674.1×	0.066	SLC1A2
detection of chemical stimulus involved in sensory perception of sour taste	1	337.0×	0.066	PKD1L3
positive regulation of mast cell differentiation	1	337.0×	0.066	PLA2G3
cardiac cell fate specification	1	337.0×	0.066	TENM4
L-aspartate transmembrane transport	1	337.0×	0.066	SLC1A2
obsolete regulation of early endosome to recycling endosome transport	1	224.7×	0.066	DNAJC13
positive regulation of cardiac muscle hypertrophy in response to stress	1	224.7×	0.066	TRPC3
axonal transport	1	168.5×	0.066	TMEM230
positive regulation of histamine secretion by mast cell	1	168.5×	0.066	PLA2G3
phosphatidylethanolamine metabolic process	1	134.8×	0.066	PLA2G3
D-aspartate import across plasma membrane	1	134.8×	0.066	SLC1A2
receptor localization to non-motile cilium	1	134.8×	0.066	TUB
visual behavior	1	112.3×	0.066	SLC1A2
positive regulation of biosynthetic process	1	112.3×	0.066	ZNF528
phosphatidic acid metabolic process	1	112.3×	0.066	PLA2G3
regulation of secretion	1	112.3×	0.066	MYO6
L-aspartate import across plasma membrane	1	112.3×	0.066	SLC1A2
positive regulation of synaptic vesicle endocytosis	1	112.3×	0.066	ABCA13
production of molecular mediator involved in inflammatory response	1	96.3×	0.066	PLA2G3
phosphatidylserine metabolic process	1	96.3×	0.066	PLA2G3
central nervous system myelin formation	1	96.3×	0.066	TENM4
positive regulation of cholesterol transport	1	96.3×	0.066	ABCA13
positive regulation of fatty acid oxidation	1	96.3×	0.066	PPARGC1A
bundle of His cell-Purkinje myocyte adhesion involved in cell communication	1	96.3×	0.066	CTNNA3
protein localization to photoreceptor outer segment	1	96.3×	0.066	TUB
positive regulation of gastrulation	1	96.3×	0.066	TENM4
neuron development	2	20.4×	0.066	LINGO1, TENM4
calcium ion transmembrane transport	2	16.9×	0.066	TRPC3, PKD1L3
phagocytosis, recognition	1	84.3×	0.070	TUB
regulation of early endosome to late endosome transport	1	84.3×	0.070	DNAJC13

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

12 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Pramipexole	Phase 3
Topiramate	Phase 3
Acamprosate	Phase 2
Brexanolone	Phase 2
Catequentinib	Phase 2
Incobotulinumtoxina	Phase 2
Methazolamide	Phase 2
Onabotulinumtoxina	Phase 2
Penpulimab	Phase 2
Perampanel	Phase 2
Zonisamide	Phase 2
Zuranolone	Phase 2

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 3 · Phased (≥1): 6 · Undrugged: 25

Druggability breadth: 12 of 31 evidence-associated genes (39%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
STK32B	NERATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
STK32B	5	4
SLC1A2	2	3
GABRR2	2	1
MMP10	2	3
TRPC3	1	2
PLA2G3	1	2
TUB	0	0
TGM4	0	0
ABCA13	0	0
CAPN6	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
NERATINIB	4	STK32B
ASPARTIC ACID	3	SLC1A2
GLUTAMIC ACID	3	SLC1A2
LINIFANIB	3	STK32B
BRIVANIB	3	STK32B
LESTAURTINIB	3	STK32B
MARIMASTAT	3	MMP10
CLEMIZOLE	2	TRPC3
PELITINIB	2	STK32B
VARESPLADIB	2	PLA2G3
CTS-1027	2	MMP10
GAMMA-AMINOBUTYRIC ACID	1	GABRR2
MUSCIMOL	1	GABRR2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
STK32B	118	Binding:118
SLC1A2	90	Binding:84, Functional:6
MMP10	52	Binding:48, Functional:3, ADMET:1
TRPC3	45	Binding:45
KCNH8	21	Binding:20, Toxicity:1
PLA2G3	18	Binding:18
GABRR2	15	Functional:14, Binding:1
PPARGC1A	12	Binding:12
GEMIN5	7	Binding:7
GPR151	3	Binding:3
DNAJC13	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
TGM4	2.3.2.13	protein-glutamine gamma-glutamyltransferase
CAPN6	3.4.22.B26
MMP10	3.4.24.22	stromelysin 2

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
STK32B	118

Pharmacogenomics

Cohort genes with a PharmGKB record: 31; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

13 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
NERATINIB	4	STK32B
ASPARTIC ACID	3	SLC1A2
GLUTAMIC ACID	3	SLC1A2
LINIFANIB	3	STK32B
BRIVANIB	3	STK32B
LESTAURTINIB	3	STK32B
MARIMASTAT	3	MMP10
CLEMIZOLE	2	TRPC3
PELITINIB	2	STK32B
VARESPLADIB	2	PLA2G3
CTS-1027	2	MMP10
GAMMA-AMINOBUTYRIC ACID	1	GABRR2
MUSCIMOL	1	GABRR2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	STK32B
B	Phased (≥1) drug, not yet approved	5	SLC1A2, TRPC3, PLA2G3, GABRR2, MMP10
C	Druggable family + PDB, no drug	2	LINGO1, GPR151
D	Druggable family + AlphaFold only, no drug	7	TGM4, ABCA13, CAPN6, KCNH8, OR5K3, OR5K4, OR6C1
E	Difficult family or no structure, no drug	16	TUB, TMEM230, GEMIN5, PKD1L3, FAM228B, CTNNA3, DNHD1, CCDC183, ZNF528, TENM4 (+6 more)

Undrugged target profiles

25 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
TUB	0	—
TGM4	0	—
ABCA13	0	—
CAPN6	0	—
TMEM230	0	—
KCNH8	21	—
GEMIN5	7	—
LINGO1	0	—
PKD1L3	0	—
GPR151	3	—
FAM228B	0	—
CTNNA3	0	—
DNHD1	0	—
CCDC183	0	—
ZNF528	0	—
TENM4	0	—
DNAJC13	1	—
SH3D19	0	—
MS4A14	0	—
OR5K3	0	—
OR5K4	0	—
FTL	0	—
MYO6	0	—
OR6C1	0	—
PPARGC1A	12	—

Clinical trials & evidence

Clinical trials

Clinical trials: 235.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	178
PHASE2	26
PHASE1	9
PHASE3	6
PHASE4	5
PHASE1/PHASE2	5
PHASE2/PHASE3	3
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00439699	PHASE4	COMPLETED	A Pilot Clinical Trial Of Memantine for Essential Tremor
NCT00584376	PHASE4	COMPLETED	Pregabalin (Lyrica) for the Treatment of Essential Tremor
NCT00998660	PHASE4	COMPLETED	RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)
NCT02111369	PHASE4	COMPLETED	Propranolol and Botulinum Toxin for Essential Vocal Tremor
NCT02495883	PHASE4	COMPLETED	Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response
NCT04748640	PHASE2/PHASE3	RECRUITING	Bilateral Essential Tremor Treatment With Gamma Knife
NCT06087276	PHASE3	ENROLLING_BY_INVITATION	Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
NCT00018564	PHASE3	COMPLETED	Novel Therapies for Essential Tremor
NCT00236496	PHASE3	COMPLETED	A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.
NCT00608231	PHASE2/PHASE3	WITHDRAWN	Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation
NCT01441284	PHASE3	WITHDRAWN	Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
NCT04193527	PHASE3	COMPLETED	A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
NCT04265209	PHASE3	COMPLETED	[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson’s Diseases and Essential Tremor
NCT05366751	PHASE2/PHASE3	TERMINATED	A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
NCT06821906	PHASE2	RECRUITING	Stereotactic Radiosurgery in the Treatment of Essential Tremor
NCT07074002	PHASE2	RECRUITING	Proof of Concept Study on BP1.4979 Effect on Essential Tremor
NCT07103265	PHASE2	NOT_YET_RECRUITING	Developing a New LIFU Neuromodulation Method to Suppress Tremor
NCT07344194	PHASE1/PHASE2	RECRUITING	Dual-Site Transcranial Magnetic Stimulation of the Supplementary Motor Area and Cerebellum for the Treatment of Essential Tremor.
NCT07484152	PHASE1/PHASE2	NOT_YET_RECRUITING	Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor
NCT00080366	PHASE2	COMPLETED	Octanol to Treat Essential Tremor
NCT00102596	PHASE2	COMPLETED	Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor
NCT00223743	PHASE2	COMPLETED	A Safety/Efficacy Trial of Zonisamide for Essential Tremor
NCT00321087	PHASE2	TERMINATED	A Study of T2000 in Essential Tremor
NCT00598078	PHASE2	COMPLETED	Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
NCT00620165	PHASE1/PHASE2	COMPLETED	Efficacy of Levetiracetam in Essential Tremor
NCT00655278	PHASE2	TERMINATED	T2000 in Essential Tremor - Open Label Continuation
NCT00848172	PHASE1/PHASE2	COMPLETED	Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor
NCT01332695	PHASE2	COMPLETED	A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
NCT02277106	PHASE2	COMPLETED	Evaluate SAGE-547 in Participants With Essential Tremor
NCT02551848	PHASE2	UNKNOWN	Kinematic-based BoNT-A Injections for Bilateral ET
NCT02668146	PHASE2	UNKNOWN	An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor
NCT02978781	PHASE2	COMPLETED	A Study to Evaluate SAGE-217 in Participants With Essential Tremor
NCT03101241	PHASE2	COMPLETED	A Phase 2 RCT Study of CX-8998 for Essential Tremor
NCT03688685	PHASE2	COMPLETED	A Clinical Study to Evaluate CAD-1883 in Essential Tremor
NCT03780426	PHASE2	COMPLETED	tSMS in Essential Tremor
NCT03805750	PHASE1/PHASE2	COMPLETED	Trial of Cannabis for Essential Tremor
NCT04305275	PHASE2	COMPLETED	A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
NCT04727658	PHASE2	TERMINATED	Linac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL)
NCT04880616	PHASE2	COMPLETED	Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
NCT05021978	PHASE2	COMPLETED	A Clinical Trial of PRAX-944 in Participants With Essential Tremor

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PROPRANOLOL	4	6
OXYBATE	4	3
ZONISAMIDE	4	2
ACAMPROSATE	4	1
ALCOHOL	4	1
ALPRAZOLAM	4	1
BREXANOLONE	4	1
MEMANTINE	4	1
METHAZOLAMIDE	4	1
ONABOTULINUMTOXINA	4	1
PERAMPANEL	4	1
PRAMIPEXOLE	4	1
PREGABALIN	4	1
PRIMIDONE	4	1
TOPIRAMATE	4	1
ZURANOLONE	4	1
DEXPRAMIPEXOLE	3	1
MAXACALCITOL	3	1
OCTANOL	2	4
DEXPROPRANOLOL	2	2
OCTANOIC ACID	2	2
SUVECALTAMIDE	2	2
T-2000	2	2
APINOCALTAMIDE	2	1
BP-14979	2	1
ISMIDENON	2	1
RIMTUZALCAP	2	1
ULIXACALTAMIDE	1	3
CHEMBL1201343	0	1
CHEMBL46909	0	1

Cohort genes: TUB, SLC1A2, TGM4, TRPC3, STK32B, ABCA13, CAPN6, TMEM230, PLA2G3, KCNH8, GEMIN5, LINGO1, PKD1L3, GPR151, FAM228B, CTNNA3, DNHD1, CCDC183, ZNF528, TENM4, DNAJC13, SH3D19, MS4A14, OR5K3, OR5K4, FTL, GABRR2, MMP10, MYO6, OR6C1, PPARGC1A
Drugs: Propranolol, Oxybate, Zonisamide, Acamprosate, Alcohol, Alprazolam, Brexanolone, Memantine, Methazolamide, Onabotulinumtoxina, Perampanel, Pramipexole, Pregabalin, Primidone, Topiramate, Zuranolone, Dexpramipexole, Maxacalcitol